ES2108642B1 - Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus. - Google Patents

Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.

Info

Publication number
ES2108642B1
ES2108642B1 ES9501603A ES9501603A ES2108642B1 ES 2108642 B1 ES2108642 B1 ES 2108642B1 ES 9501603 A ES9501603 A ES 9501603A ES 9501603 A ES9501603 A ES 9501603A ES 2108642 B1 ES2108642 B1 ES 2108642B1
Authority
ES
Spain
Prior art keywords
tungsten
compositions
pharmaceutical compositions
diabetes mellitus
oral treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES9501603A
Other languages
English (en)
Spanish (es)
Other versions
ES2108642A1 (es
Inventor
Cirera Joan Josep Guinovart
Lluis Albert Barbera
Gil Joan Enric Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Hispania SL
Original Assignee
Quimica Farmaceutica Bayer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/504,020 priority Critical patent/US5595763A/en
Application filed by Quimica Farmaceutica Bayer SA filed Critical Quimica Farmaceutica Bayer SA
Priority to ES9501603A priority patent/ES2108642B1/es
Priority to EP96500106A priority patent/EP0755681A1/en
Priority to JP19733096A priority patent/JPH09118624A/ja
Publication of ES2108642A1 publication Critical patent/ES2108642A1/es
Application granted granted Critical
Publication of ES2108642B1 publication Critical patent/ES2108642B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES9501603A 1995-07-19 1995-07-26 Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus. Expired - Fee Related ES2108642B1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US08/504,020 US5595763A (en) 1995-07-19 1995-07-19 Tungsten (VI) compositions for the oral treatment of diabetes mellitus
ES9501603A ES2108642B1 (es) 1995-07-26 1995-07-26 Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
EP96500106A EP0755681A1 (en) 1995-07-19 1996-07-25 Tungsten (VI) compositions for the oral treatment of diabetes mellitus
JP19733096A JPH09118624A (ja) 1995-07-26 1996-07-26 真性糖尿病の経口処置用タングステン（ｖｉ）組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9501603A ES2108642B1 (es) 1995-07-26 1995-07-26 Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.

Publications (2)

Publication Number Publication Date
ES2108642A1 ES2108642A1 (es) 1997-12-16
ES2108642B1 true ES2108642B1 (es) 1998-08-16

Family

ID=8291317

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9501603A Expired - Fee Related ES2108642B1 (es) 1995-07-19 1995-07-26 Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.

Country Status (2)

Country Link
JP (1) JPH09118624A (https=)
ES (1) ES2108642B1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2187276B1 (es) 2001-05-16 2004-08-01 Quimica Farmaceutica Bayer,S.A. Composiciones orales para el tratamiento de humanos obesos y no diabeticos.
US20080206356A1 (en) * 2005-07-29 2008-08-28 Universidad De Barcelona Pharmaceutical Compositions for the Treatment of Neurodegenerative Disorders
CN100515428C (zh) * 2007-04-26 2009-07-22 暨南大学 钨酸锂在制药中的应用
ES2478696B1 (es) * 2012-12-21 2015-05-06 Universitat De Barcelona Sales de tungstato como agentes antiplaquetarios
ES2478790B1 (es) * 2013-01-22 2015-05-06 Oxolife, S. L. Uso de sales de tungsteno (VI) para el tratamiento de la infertilidad femenina en mamíferos no diabéticos
ES2551828B1 (es) * 2014-05-21 2016-09-12 Oxolife S.L. Composiciones alimentarias que comprenden sales de tungsteno (VI)
KR102282865B1 (ko) * 2014-07-21 2021-07-28 옥소라이프, 에스.엘. 비당뇨병 암컷 포유류에서 불임 치료를 위해, 수정 및 정상 생식을 자극하기 위해, 및 보조 생식 기술의 효과를 개선하기 위해 사용되는 텅스텐(vi) 염

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6025928A (ja) * 1983-07-21 1985-02-08 Tanaka Seinosuke 薬剤
JPS6025916A (ja) * 1983-07-21 1985-02-08 Tanaka Seinosuke 入浴水

Also Published As

Publication number Publication date
ES2108642A1 (es) 1997-12-16
JPH09118624A (ja) 1997-05-06

Similar Documents

Publication Publication Date Title
BR0015295A (pt) Formulação e método antidiabético
DE69928006T2 (de) Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
PT693924E (pt) Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
NZ217483A (en) Composition for delivery of hydrophobic drugs
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
DK0416951T3 (da) Lægemidler indeholdende salmeterol og fluticason
CR6458A (es) Composiciones de valdecoxib
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
ES2089027T3 (es) Forma de dosificacion transmucosica.
ES2052542T3 (es) Composiciones de hormonas del crecimiento, de liberacion sostenida, para administracion por via parenteral y su uso.
RU94022479A (ru) Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат
ATE191719T1 (de) Analoge des calcitonin aus lachs, ihre herstellung und ihre verwendung als medizin und als analytische reagentien
ES2170813T3 (es) Acidos 2,2-dicloroalcanocarboxilicos, proceso para su preparacion, medicamentos que los contienen y su uso para tratar la resistencia a la insulina.
ATE92762T1 (de) Medikamente.
AR008387A1 (es) Nuevas 5-fenoxialquil-tiazolidin-2,4-dionas, procedimientos para obtenerlas, nuevos compuestos intermedios de estos procedimientos ycomposiciones farmaceuticas que contienen las nuevas 5-fenoxialquil-tiazolidin- 2,4-dionas
EP0185210A2 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
ES2108642B1 (es) Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
US6589995B2 (en) Method of inhibiting pancreatic β-cell p135 O-glycosylation
ATE13488T1 (de) Gallium-chlorid, ein neues antikrebsmittel.
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
BR0111464A (pt) Composição farmacêutica na forma de dosagem unitária, e, método de tratamento de um paciente com nefropatia diabética
Anderson et al. Acute Toxicity of Trypan Blue, Gentian Violet and Brilliant Green.

Legal Events

Date Code Title Description
PC2A Transfer granted

Owner name: QUIMICA FARMACEUTICA BAYER, S.A.

FD1A Patent lapsed

Effective date: 20100528